Company news
Bioasis Technologies Inc. (OTC:BIOAF) news
Bioasis Technologies Inc. news releases on 6ix. Latest, May 30, 2018: Bioasis Announces Publication of Independent Validation of the Company’s xB3 ™ Platform…
Press releases — page 3
Bioasis Announces Publication of Independent Validation of the Company’s xB3 ™ Platform Technology
May 30, 2018
Uptick Newswire’s “Stock Day” Podcast Welcomes Dr. Mark Day of Bioasis Technologies Inc.
May 29, 2018
Bioasis Announces Closing of Second Tranche of Previously Disclosed Private Placement
May 24, 2018
Bioasis and WuXi Biologics Announce Initial Strategic Collaboration for the Development and Manufacturing of xB3-001, the Company’s Lead Investigational Candidate to Treat Brain Cancer
May 21, 2018
Bioasis Announces Closing of First Tranche of Previously Disclosed Private Placement
May 17, 2018
Bioasis Announces Private Placement and Intention to Pursue NASDAQ Listing
May 14, 2018
Bioasis Announces Key Strategic Appointment to its Senior Leadership Team with Addition of Caroline Hill, Ph.D., Leading Research & Development Operations
March 26, 2018
Bioasis Appoints Deborah Rathjen, B.Sc. (Hons), Ph.D., MAICD, FTSE as Chair of the Board of Directors
March 21, 2018
Bioasis to Present at the 20th Annual BIO CEO & Investor Conference
February 6, 2018
Bioasis Announces Filing of Quarterly Financial Statements and MD&A
January 30, 2018
Bioasis Implements Transition Plan for Its Board of Directors
December 4, 2017
Bioasis Establishes U.S. Presence with Office in Connecticut
October 10, 2017
biOasis Appoints Christopher P. Lowe, M.B.A. as Chief Financial Officer and Board Advisor
October 2, 2017
biOasis Welcomes Dr. Nancy Stagliano, Dr. Deborah Rathjen and Dr. Maha Radhakrishnan to Its Board of Directors
September 25, 2017
biOasis Announces Voting Results for 2017 Annual Meeting
September 21, 2017
biOasis Announces Rob Hutchison, Founder, to Retire as Chairman & Board Member
September 18, 2017
biOasis Announces Formation of Scientific Advisory Board to Advance the Science for the Company’s Blood-Brain Barrier Drug Delivery Platform
September 7, 2017
biOasis Announces Nominees to the Board of Directors, Chairman Transition and Details of its Annual General Meeting of Shareholders
August 28, 2017
biOasis Appoints Doug Williams, MBA, Executive Vice President, Chief Business Officer
August 21, 2017
biOasis Appoints Catherine London, Executive Vice President, Head of Corporate Communications and Investor Relations
June 25, 2017
biOasis Engages FreeMind Group to Access Non-Dilutive Global Funding Opportunities
June 15, 2017
biOasis CEO Dr. Mark Day Releases Details of Corporate Plans in Message to Shareholders
June 13, 2017
biOasis to Present at The Global Chinese Financial Forum - Shanghai Conference 2017
June 8, 2017
biOasis to Present at the 16th International Postgraduate Course on Lysosomal Storage Disorders
June 4, 2017
biOasis Appoints Mark Day, Ph.D., as Chief Executive Officer and Director
April 24, 2017
biOasis Closes Oversubscribed Non-Brokered Private Placement
April 11, 2017
biOasis Announces Oversubscription of Financing
March 31, 2017
biOasis Provides AGM Update -- Expanding The biOasis Deal Flow Pipeline
January 22, 2017
biOasis Announces Assignment of IR Agreement
January 19, 2017
biOasis Attends BIO Europe and the Lockman BT2111 Paper is Honored by being Featured on the Cover of Pharmaceutical Research's December Journal
November 6, 2016
biOasis Provides Further Details Regarding its Agreement with Rising Tide Equity
October 25, 2016
biOasis Engages Rising Tide Equity to Increase Global Awareness
October 23, 2016
biOasis Enters Into a License Agreement With Vaccinex Inc.
September 20, 2016
biOasis Announces Publication of Scientific Paper -- Transcend-Based Anti-Cancer Antibody BT2111 Crosses the Blood-Brain Barrier and Shows Efficacy in the Treatment of Metastatic HER2+ Breast Cancer Tumors in the Brains of Animal Model
August 29, 2016
biOasis Announces the Issuance of an Additional US Patent for the Delivery of Therapeutic Agents Across the Blood-Brain Barrier
July 10, 2016
biOasis Technologies Enters Into a License Agreement With Astellas Research Institute of America LLC
April 21, 2016
biOasis to Present at the Brains for Brain 10th Annual Workshop and Open Conference in Madrid, Spain
March 17, 2016
biOasis Announces Shares for Services Settlement
February 29, 2016
biOasis Technologies Inc. to Present at the 1st Annual Neuroscience BioPartnering and Investment Forum in New York on February 23, 2016
February 11, 2016
biOasis Announces the Issuance of a US Patent for the Delivery of Therapeutic Agents Across the Blood-Brain Barrier Using Polypeptides Derived From the Transcend Protein Delivery Vector
November 29, 2015
OTC Markets Group Welcomes Newly Verified OTCQB Companies – September 29
September 29, 2015
biOasis Announces Listing on OTCQB Exchange
September 28, 2015
biOasis Announces Extension of Share Purchase Warrants
August 14, 2015
biOasis Announces the Successful Delivery to the CNS of an Enzyme Used to Treat Hunter Syndrome
July 31, 2015
biOasis Technologies Inc. and Brigham and Women's Hospital Inc., Enter a Neuro-Oncology Research & Collaboration Agreement
July 21, 2015
biOasis Engages Kilmer Lucas for Cross-Border Investor Relations
June 8, 2015
biOasis Enters Into A Collaborative Research and Joint Funding Support Agreement Entitled "Focus on Brain"
May 27, 2015
biOasis Provides Scientific Updates on Its Transcend Programs
May 12, 2015
biOasis European Patent Granted for The Use of Transcend for the Delivery of Enzymes to Treat Lysosomal Storage Disease in The Brain
April 21, 2015
biOasis Releases Results From an Ischemic Stroke Model with Transcend BBB Carrier Peptide (MTfp):MTfp-siRNA Reduces Both the Damage Caused by Infarct and Significantly Improves Neurological Score
March 16, 2015